| ***Variable*** | ***No Severe PGD (n = 54)*** | ***Severe PGD (n = 8)*** | ***Total*** | ***p*** | ***test*** |
| --- | --- | --- | --- | --- | --- |
| demographics\_age\_tpx | 56.2 [46.2–61.1] | 59.1 [47.7–62.6] | 56.6 [46.2–61.3] | 0.508 | Wilcoxon rank-sum |
| demographics\_race: Asian | 3 (6%) | 1 (12%) | 4 (6%) | 0.204 | Fisher exact |
| demographics\_race: Black | 31 (57%) | 2 (25%) | 33 (53%) | 0.204 | Fisher exact |
| demographics\_race: Hispanic | 2 (4%) | 0 (0%) | 2 (3%) | 0.204 | Fisher exact |
| demographics\_race: White | 18 (33%) | 5 (62%) | 23 (37%) | 0.204 | Fisher exact |
| demographics\_sex: Male | 37 (69%) | 5 (62%) | 42 (68%) | 0.705 | Fisher exact |
| demographics\_BMI | 25.9 ± 4.9 | 29 ± 3 | 26.3 ± 4.8 | 0.028 | t-test |
| comorbidities\_smoking\_hx: Y | 15 (28%) | 3 (38%) | 18 (29%) | 0.681 | Fisher exact |
| comorbidities\_DM: Y | 18 (33%) | 4 (50%) | 22 (35%) | 0.438 | Fisher exact |
| comorbidities\_prior\_cardiac\_surg: Y | 20 (37%) | 3 (38%) | 23 (37%) | 1.000 | Fisher exact |
| recipient\_NICM\_ICM\_cong: Congenital | 3 (6%) | 0 (0%) | 3 (5%) | >0.999 | Fisher exact |
| recipient\_NICM\_ICM\_cong: ICM | 11 (20%) | 2 (25%) | 13 (21%) | >0.999 | Fisher exact |
| recipient\_NICM\_ICM\_cong: NICM | 40 (74%) | 6 (75%) | 46 (74%) | >0.999 | Fisher exact |
| preop\_temp\_MCS: Y | 33 (61%) | 5 (62%) | 38 (61%) | >0.999 | Fisher exact |
| preop\_IABP: Y | 2 (4%) | 0 (0%) | 2 (3%) | >0.999 | Fisher exact |
| preop\_imeplla5.5: Y | 32 (59%) | 4 (50%) | 36 (58%) | 0.710 | Fisher exact |
| preop\_VA\_ECMO: Y | 2 (4%) | 2 (25%) | 4 (6%) | 0.077 | Fisher exact |
| preop\_LVAD: Y | 10 (19%) | 2 (25%) | 12 (19%) | 0.645 | Fisher exact |
| recipient\_UNOS\_status | 2 [2–2] | 2 [1.8–4] | 2 [2–2] | 0.416 | Wilcoxon rank-sum |
| preop\_PVR | 2.1 [1.4–2.9] | 2.2 [2–2.5] | 2.1 [1.4–2.8] | 0.787 | Wilcoxon rank-sum |
| rx\_preop\_inotrope: Y | 37 (69%) | 4 (50%) | 41 (66%) | 0.426 | Fisher exact |
| rx\_preop\_amiodarone: Y | 17 (31%) | 3 (38%) | 20 (32%) | 0.705 | Fisher exact |
| preop\_RADIAL\_calc | 3 [2–4] | 3 [2–4] | 3 [2–4] | 0.750 | Wilcoxon rank-sum |
| rx\_preop\_ASA: Y | 20 (37%) | 2 (25%) | 22 (35%) | 0.700 | Fisher exact |
| preop\_labs\_albumin | 3.8 [3.4–4.2] | 3.6 [3.4–4.2] | 3.8 [3.4–4.2] | 0.982 | Wilcoxon rank-sum |
| preop\_labs\_alkphos | 78 [63–88.5] | 68.5 [53–78.5] | 73 [62–88.5] | 0.352 | Wilcoxon rank-sum |
| preop\_labs\_ALT | 20 [13–30] | 44.5 [22.8–50.2] | 22 [13.5–39.5] | 0.082 | Wilcoxon rank-sum |
| preop\_labs\_AST | 22 [18.5–33] | 33.5 [29–42] | 25 [19–34.5] | 0.047 | Wilcoxon rank-sum |
| preop\_labs\_bilirubin | 0.6 [0.4–1.1] | 0.8 [0.5–1.2] | 0.6 [0.4–1.1] | 0.441 | Wilcoxon rank-sum |
| preop\_labs\_creatinine | 1.3 [1–1.7] | 1.2 [0.9–1.3] | 1.3 [1–1.7] | 0.425 | Wilcoxon rank-sum |
| preop\_labs\_GFR | 61.4 ± 25.2 | 68.6 ± 30.1 | 62.3 ± 25.7 | 0.532 | t-test |
| preop\_labs\_Hgb | 10.6 ± 1.9 | 10.3 ± 3.3 | 10.6 ± 2.1 | 0.810 | t-test |
| preop\_labs\_Plt | 182.5 [156–228] | 159.5 [142.5–207] | 179.5 [153.5–227] | 0.372 | Wilcoxon rank-sum |
| preop\_labs\_sodium | 133.5 ± 4.2 | 133.4 ± 3.7 | 133.5 ± 4.1 | 0.923 | t-test |
| preop\_labs\_WBC | 7 [6.1–9.3] | 8.8 [7.9–9.5] | 7.3 [6.3–9.3] | 0.133 | Wilcoxon rank-sum |

*Statistical Methods: For continuous variables, normality was assessed using the Shapiro-Wilk test. For 2-group comparisons, normally distributed variables were compared using Welch’s t-test; non-normal distributions were compared using the Wilcoxon rank-sum test. For 3-group comparisons, normally distributed variables were compared using one-way ANOVA; non-normal or ordinal variables specified by the user were compared using the Kruskal-Wallis test. Categorical variables were compared using Chi-squared tests or Fisher’s exact tests if expected counts were <5. Ordinal variables were summarized as medians [IQR] and compared using appropriate non-parametric tests. Note: Approximate p-values were used for non-parametric tests with tied data.*